Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $19
Canaccord Genuity analyst Caitlin Cronin maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $15 to $19.
Stocks · News reference
Under the Radar: 3 Boring Small Caps That Could Return 10x
Investors spend an enormous amount of time searching for the next stock that can rise 10 times in value. They study disruptive technologies, enormous addressable markets, charismatic founders, and whatever investment
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cantor Fitzgerald Reiterates Overweight on Bioventus, Maintains $15 Price Target
Cantor Fitzgerald analyst Sarah James reiterates Bioventus (NASDAQ:BVS) with a Overweight and maintains $15 price target.
Deal Dispatch: Bending Spoons Acquires Airtable, Bain Capital Buys Gong Cha Global, Salad and Go Bankruptcy
Major M&A deals include Visa buys BioCatch, Apollo Global nabs EasyJet, QVC emerges from Chapter 11 bankruptcy.
Bioventus shares are trading higher after the company reported strong Q2 financial results and announced a review of strategic alternatives.
Coda Octopus Group Q3 2026 Earnings Call Transcript
Coda Octopus Group (NASDAQ:CODA) held its third-quarter earnings conference call on Monday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and
Coda Octopus Group Q3 EPS $0.12, Inline, Sales $7.717M Beat $7.260M Estimate
Coda Octopus Group (NASDAQ:CODA) reported quarterly earnings of $0.12 per share which met the analyst consensus estimate. This is a 9.09 percent increase over earnings of $0.11 per share from the same period last year.